Accepted Preprint (first posted online 22 August 2013)

    Olfactory Receptor 51E1 as a Novel Target in Somatostatin Receptor Negative Lung Carcinoids

    1. Apostolos V Tsolakis
    1. V Giandomenico, Department of Medical Sciences, Endocrine Oncology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden
    2. T Cui, Department of Medical Sciences, Endocrine Oncology, Uppsala University, Uppsala, Sweden
    3. L Grimelius, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, United States
    4. K Oberg, Dept. of Endocrine Oncology, Uppsala, SE-751 85, Sweden
    5. G Pelosi, Division of Pathology and Laboratory Medicine, European Institute of Oncology and Department of Biomedical and Clinical Sciences "Luigi Sacco", University of Milan School of Medicine, European Institute of Oncology and University of Milan School of Medicine, Milan, Italy
    6. A Tsolakis, Department of Medical Sciences, Endocrine Oncology, Uppsala University, Uppsala, Sweden
    1. Correspondence: Apostolos Tsolakis, Email: apostolos.tsolakis{at}medsci.uu.se

    Abstract

    Somatostatin receptors (SSTRs) may be used in lung carcinoids (LCs) for diagnosis and therapy, although additional targets are clearly warranted. This study aimed to investigate whether olfactory receptor 51E1 (OR51E1) may be a potential target for LCs. OR51E1 coding sequence was analyzed in LC cell lines, NCI-H727 and NCI-H720. OR51E1 transcript expression was investigated in LC cell lines and frozen specimens by quantitative real-time PCR. OR51E1, SSTR2, SSTR3, and SSTR5 expression was evaluated by immunohistochemistry on paraffin-embedded sections of 73 typical carcinoids (TCs), 14 atypical carcinoids (ACs) and 11 regional/distant metastases, and compared to OctreoScan data. Immunohistochemistry results were rendered semiquantitatively on a scale from 0 to 3+, taking into account the cellular compartmentalization (membrane vs. cytoplasm) and the percentage of tumor cells (<50% vs. >50%). Our results showed that wild-type OR51E1 transcript was expressed in both LC cell lines. OR51E1 mRNA was expressed in 9/12 TCs and 7/9 ACs (p=NS). Immunohistochemically, OR51E1, SSTR2, SSTR3 and SSTR5 were detected in 85%, 71%, 25% and 39% of TCs, and in 86%, 79%, 43% and 36% of ACs, respectively. OR51E1 immunohistochemical scores were higher or equal compared to SSTRs in 79% of TCs and 86% of ACs. Furthermore, in the LC cases where all SSTR subtypes were lacking, membrane OR51E1 expression was detected in 10/17 TCs and 1/2 ACs. Moreover, higher OR51E1 immunohistochemical scores were detected in 5/6 OctreoScan-negative LC lesions. Therefore, the high expression of OR51E1 in LCs makes it a potential novel diagnostic target in SSTR-negative tumors.

    • Received 11 July 2013
    • Revision received 13 August 2013
    • Accepted 22 August 2013
    • Accepted Preprint first posted online on 22 August 2013